Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 dose escalation, first in man trial of CAD-1883

Trial Profile

Phase 1 dose escalation, first in man trial of CAD-1883

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Nov 2018

At a glance

  • Drugs CAD-1883 (Primary)
  • Indications Ataxia; Essential tremor; Spinocerebellar ataxias
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 15 Nov 2018 Results published in the Saniona Media Release
    • 12 Mar 2018 According to a Cadent Therapeutics media release, status changed from planning to recruiting.
    • 17 Oct 2017 According to a Saniona media release, Luc Therapeutics changed its name to Cadent Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top